Form 8-K - Current report:
SEC Accession No. 0001558370-25-010850
Filing Date
2025-08-08
Accepted
2025-08-08 08:01:13
Documents
13
Period of Report
2025-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20250808x8k.htm   iXBRL 8-K 33070
2 EX-99.1 kala-20250808xex99d1.htm EX-99.1 116818
  Complete submission text file 0001558370-25-010850.txt   270120

Data Files

Seq Description Document Type Size
3 EX-101.SCH kala-20250808.xsd EX-101.SCH 3451
4 EX-101.LAB kala-20250808_lab.xml EX-101.LAB 15264
5 EX-101.PRE kala-20250808_pre.xml EX-101.PRE 9656
15 EXTRACTED XBRL INSTANCE DOCUMENT kala-20250808x8k_htm.xml XML 4628
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 251196253
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)